Entera Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>EB</div>
ENTX -- USA Stock  

USD 1.30  0.03  2.26%

While some planning is required to successfully invest in stocks, sometimes taking bold action is just as important. Let's try to break down why this may be the case with Entera Bio. We will evaluate why recent Entera Bio price moves suggest a bounce in September. Entera Bio is currently traded for 1.40. The entity has historical hype elasticity of 0.01. The average price elasticity to hype of competition is about 0.8. The firm is forecasted to increase in value after the next headline, with the price going to jump to 1.54. The current volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is estimated to be 0.65%, whereas the daily expected return is currently at -0.45%. The volatility of related hype on Entera Bio is about 232.06% with expected price after next announcement by competition of 2.2 Given the investment horizon of 30 days, the next forecasted press release will be very soon.
Published over a month ago
View all stories for Entera Bio | View All Stories
What is September outlook for Entera Bio (NASDAQ:ENTX)?
We provide trade advice to complement the prevailing expert consensus on Entera Bio. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
The successful prediction of Entera Bio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Entera Bio, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Entera Bio based on Entera Bio hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Entera Bio's related companies.

Watch out for price decline

Please consider monitoring Entera Bio on a daily bases if you are holding a position in it. Entera Bio is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Entera Bio stock to be traded above the $1 level to remain listed. If Entera Bio stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Entera expected Price

Entera Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Entera Bio technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Entera Bio trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Entera utilizes its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (8.92 Million) in 2019

A Deeper Perspective

Entera Bio reported the previous year's revenue of 278 K. Net Loss for the year was (10.72 M) with profit before overhead, payroll, taxes, and interest of 26 K.
 2010 2019 2020 (projected)
Revenues USD500 K236 K279.16 K
Revenues500 K236 K279.16 K

Deferred Revenue Breakdown

Entera Bio Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2020. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Entera Bio Deferred Revenue is fairly stable at the moment as compared to the past year. Entera Bio reported Deferred Revenue of 267,000 in 2019

Anything left for Entera Bio after the slide?

The skewness is down to 0.65 as of today. As of the 20th of August, Entera Bio shows the coefficient of variation of (56,711), and Mean Deviation of 5.17. Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Entera Bio, which can be compared to its rivals. Please confirm Entera Bio variance and potential upside to decide if Entera Bio is priced favorably, providing market reflects its regular price of 1.4 per share. Please also check Entera Bio total risk alpha, which is currently at (1.74) to verify the company can sustain itself at a future point.

Our Bottom Line On Entera Bio

While some firms in the biotechnology industry are either recovering or due for a correction, Entera may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Entera nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Entera Bio.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com